|
Proteomics is a rapidly evolving field that is rife with commercial opportunities as the technology achieves ever higher throughput at lower cost and greater
sensitivity.
Proteomics: Current State and Future Directions is a CHI Insight Pharma report that delivers an up-to-the-minute assessment of the state of
proteomics and its applications in drug and biomarker discovery. The report provides insight into:
- Strengths and weaknesses of the leading technologies for protein separation, detection, and quantification - with an emphasis on high-throughput approaches
- The fundamental challenge posed by the vast dynamic range among protein concentrations, and the potential solutions in development and entering the market
- Recent applications of proteomics to discover biomarkers for preeclampsia, and for neonatal ureteropelvic junction, and to differentiate between diagnosis of ALS and Parkinson’s disease
- Technologies such as mass spectrometry, antibody-bearing chips, and solution array multiplexing to address the challenge of detecting low-abundance proteins
- The most significant research initiatives and recent product introductions, company profiles, and the major deals and M&As that are shaping the proteomics landscape
|
A quantitative survey (N=81) of individuals involved with proteomics at
biopharmaceutical and diagnostic firms, vendors of equipment and services, and academic research departments sheds light on current practices and future directions in the use of proteomics in pharmaceutical R&D. Among the highlights:
|
Expert interviews with 3 authorities on proteomics provide penetrating commercial and scientific insights into the state
of the art. Roger Brent, PhD (president and research director of the Molecular Sciences Institute in
Berkeley, CA, and cofounder of Aptanomics SA) examines the commercial opportunity and economic realities of using
proteomics in the clinic. Gilbert S. Omenn, MD, PhD (co-director of the Human Proteome Organization’s Plasma Proteome Project and professor/director of the Center for Computational Medicine and Biology at the
University of Michigan) discusses solutions for overcoming the problem of high protein concentration in plasma samples. James R. Heath, PhD (professor of chemistry at California Institute of Technology) shares his vision
of dynamic, multiparameter network models, driven by nanotechnology, that describe how biological systems change over
time.
About the Author
James Kling has been writing about biotechnology and drug discovery for more than a decade. His work has appeared in Science, Nature Biotechnology, Scientific American, and WebMD, among other publications.
| 
